Next Article in Journal
Digital Impressions in Implant Dentistry: A Literature Review
Next Article in Special Issue
Relationship between Fixed Dental Crowns and Volatile Sulphur Compounds
Previous Article in Journal
Effectiveness of Complementary Therapies in Cancer Patients: A Systematic Review
Previous Article in Special Issue
Blood Pressure and Tooth Loss: A Large Cross-Sectional Study with Age Mediation Analysis
Open AccessCase Report

Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series

Department of General Dentistry and Implants, Faculty of Medicine and Dentistry, University of Murcia, 30008 Murcia, Spain
*
Author to whom correspondence should be addressed.
Int. J. Environ. Res. Public Health 2021, 18(3), 1018; https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18031018
Received: 17 December 2020 / Revised: 19 January 2021 / Accepted: 21 January 2021 / Published: 24 January 2021
(This article belongs to the Special Issue Oral Health and Diseases)
Medication-induced jaw osteonecrosis (MRONJ) is a rare and serious disease with a negative impact on patients’ quality of life, whose exact cause remains unclear and which may have a multifactorial origin. Although there are different therapeutic protocols, there is still no consensus. This case series evaluated three patients diagnosed with staged 2 MRONJ treated at the University of Murcia dental clinic according to the protocols described by the Spanish Society of Oral and Maxillofacial Surgery and the American Association of Oral and Maxillofacial Surgeons. Within 12 months of the application of therapeutic protocols, the lesions were completely healed in all cases. Radiography showed slow but progressive healing with normal bone structure. Conservative treatment with antibiotics, chlorhexidine rinses and minimally invasive surgical intervention with necrotic bone resection is effective in treating stage 2 of MRONJ. In cases of refractory osteonecrosis, the application of platelet and leukocyte-rich fibrin (PRF-L) in the surgical approach improves the outcome in soft tissue healing and bone regeneration but further research is needed to confirm its effectiveness. View Full-Text
Keywords: osteonecrosis; medication-induced maxillary osteonecrosis; bisphosphonates; denosumab; osteonecrosis treatment osteonecrosis; medication-induced maxillary osteonecrosis; bisphosphonates; denosumab; osteonecrosis treatment
Show Figures

Graphical abstract

MDPI and ACS Style

Pardo-Zamora, G.; Martínez, Y.; Moreno, J.A.; Ortiz-Ruíz, A.J. Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series. Int. J. Environ. Res. Public Health 2021, 18, 1018. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18031018

AMA Style

Pardo-Zamora G, Martínez Y, Moreno JA, Ortiz-Ruíz AJ. Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series. International Journal of Environmental Research and Public Health. 2021; 18(3):1018. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18031018

Chicago/Turabian Style

Pardo-Zamora, Guillermo; Martínez, Yanet; Moreno, Jose A.; Ortiz-Ruíz, Antonio J. 2021. "Treatment of Stage 2 Medication-Induced Osteonecrosis of the Jaw: A Case Series" Int. J. Environ. Res. Public Health 18, no. 3: 1018. https://0-doi-org.brum.beds.ac.uk/10.3390/ijerph18031018

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop